Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Related to this article
The IMpactMF trial is being discontinued after an IDMC advised that imetelstat was unlikely to improve OS in relapsed/refractory myelofibrosis.
Advertisement
Advertisement
Trending on OncLive
1
Early Cancer Detection and Translational Biology Are Set to Shape the Future of Oncology
2
Tocilizumab Prophylaxis, Caregiver Readiness, and Chair Time Shape Community Bispecific Programs in R/R Myeloma
3
Treatment Selection and Biomarker Testing at Platinum Resistance
4
How Biomarkers Now Drive First-Line Therapy in mHSPC
5